GH Research (GHRS) Share-based Compensation (2021 - 2025)
GH Research's (GHRS) quarterly Share-based Compensation came in at $2.7 million in Q4 2025, up 249.93% year-on-year from $759000.0 in Q4 2024, and up 13.8% quarter-over-quarter from $2.3 million in Q3 2025.
GH Research (GHRS) Share-based Compensation (2021 - 2025) Analysis & Trends
GH Research's Share-based Compensation history runs 5 years deep, the most recent figure standing at $2.7 million for Q4 2025.
- On a quarterly basis, Share-based Compensation rose 249.93% year-over-year to $2.7 million in Q4 2025; TTM through Dec 2025 was $8.5 million, a 626.22% increase from a year earlier, with the FY2025 full-year figure at $13.1 million, up 167.72% from the prior year.
- Share-based Compensation rose to $2.7 million in Q4 2025 per GHRS's latest filing, from $2.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $2.7 million in Q4 2025 and bottomed at -$138000.0 in Q2 2024.
- The 5-year median for Share-based Compensation is $477000.0 (2022), against an average of $778888.9.
- Across the five-year window, Share-based Compensation tumbled 130.6% in 2024 and surged 1461.59% in 2025, its largest moves.
- Year by year, Share-based Compensation stood at $235000.0 in 2021, then jumped by 107.66% to $488000.0 in 2022, then soared by 31.56% to $642000.0 in 2023, then advanced by 18.22% to $759000.0 in 2024, then jumped by 249.93% to $2.7 million in 2025.
- Per Business Quant, the three latest GHRS Share-based Compensation figures stand at $2.7 million (Q4 2025), $2.3 million (Q3 2025), and $1.9 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 3.20 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 87.30 Mn |
| 10 | GH Research | 1.65 Bn | 1.65 Bn | - | 2.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.66 Mn |
| Dec 31, 2025 | 2.66 Mn |
| Sep 30, 2025 | 2.33 Mn |
| Sep 30, 2025 | 2.33 Mn |
| Jun 30, 2025 | 1.88 Mn |
| Jun 30, 2025 | 1.88 Mn |
| Mar 31, 2025 | 1.64 Mn |
| Mar 31, 2025 | 1.64 Mn |
| Dec 31, 2024 | 759,000.00 |
| Dec 31, 2024 | 759,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Sep 30, 2024 | 273,000.00 |
| Jun 30, 2024 | -138,000.00 |
| Jun 30, 2024 | -138,000.00 |
| Mar 31, 2024 | 277,000.00 |
| Mar 31, 2024 | 277,000.00 |
| Dec 31, 2023 | 642,000.00 |
| Dec 31, 2023 | 642,000.00 |
| Sep 30, 2023 | 647,000.00 |
| Sep 30, 2023 | 647,000.00 |